Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma

Clinical trials of combined IDO/PD1 blockade in metastatic melanoma (MM) failed to show additional clinical benefit compared to PD1-alone inhibition. We reasoned that a tryptophan-metabolizing pathway other than the kynurenine one is essential. We immunohistochemically stained tissues along the nevu...

Descripción completa

Detalles Bibliográficos
Autores principales: Oldan, Jorge D., Giglio, Benjamin C., Smith, Eric, Zhao, Weiling, Bouchard, Deeanna M., Ivanovic, Marija, Lee, Yueh Z., Collichio, Frances A., Meyers, Michael O., Wallack, Diana E., Abernethy-Leinwand, Amber, Long, Patricia K., Trembath, Dimitri G., Googe, Paul B., Kowalski, Madeline H., Ivanova, Anastasia, Ezzell, Jennifer A., Nikolaishvili-Feinberg, Nana, Thomas, Nancy E., Wong, Terence Z., Ollila, David W., Li, Zibo, Moschos, Stergios J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142396/
https://www.ncbi.nlm.nih.gov/pubmed/37123046
http://dx.doi.org/10.1080/2162402X.2023.2204753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142396/
https://www.ncbi.nlm.nih.gov/pubmed/37123046
http://dx.doi.org/10.1080/2162402X.2023.2204753

Ejemplares similares